ImmuCell 2025 revenue rises 4.3%, net loss narrows

ImmuCell

04/03/2026 21:34

Overview

Animal health firm's 2025 revenue grew 4.3% yr/yr

Net loss for 2025 improved to $1.0 mln from $2.2 mln in 2024

Company's gross profit margin rose to 41.4% from 30% in 2024

Outlook

Company expects positive results from investments in commercial expansion and manufacturing improvements

ImmuCell focuses on expanding its First Defense franchise

Result Drivers

GROSS MARGIN IMPROVEMENT - Co attributed significant improvement in gross margin to higher volumes, manufacturing efficiencies, and price realization

INCREASED OUTPUT - Manufacturing team increased average monthly output from 345,000 units in 2024 to 380,000 units in 2025

NON-RECURRING EXPENSES - Net loss affected by $2.7 mln Re-Tain asset write-down, $651,000 colostrum inventory write-downs, and $297,000 CEO transition expenses

Company press release: ID:nGNX6gDCNv

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY EPS
-$0.12
FY Net Income
-$1.04 mln
FY Operating Expenses
$9.80 mln
FY Pretax Profit
-$1.03 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)